Simcere Of China, OSI Of U.S. Sign Development Deal For Cancer Drug
This article was originally published in PharmAsia News
Executive SummaryChina's Simcere has signed an agreement with U.S.-based OSI Pharmaceuticals to take from development to marketing OSI's OSI-930 KDR/Kit inhibitor for treating various cancers
You may also be interested in...
Xellia has added a 500mg/100ml variant to its range of vancomycin ready-to-use bags in the US, while Kabi has introduced ertapenem 1g vials and struck a critical-care supply deal with Vizient.
Rather than blame employees for ignoring 397 product complaints, Teligent should have fixed complaint handling system, US FDA warning letter says.
Patent litigation settlements have paved the way for Endo’s Par and Teva to secure the first US approvals for generic versions of Novartis’ Afinitor everolimus brand.